VALBIOTIS SA (ALVAL.PA) Fundamental Analysis & Valuation

EPA:ALVAL • FR0013254851

1.008 EUR
-0.04 (-3.82%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This ALVAL.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, ALVAL scores 2 out of 10 in our fundamental rating. ALVAL was compared to 83 industry peers in the Biotechnology industry. ALVAL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ALVAL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. ALVAL.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALVAL has reported negative net income.
  • In the past year ALVAL has reported a negative cash flow from operations.
  • In the past 5 years ALVAL always reported negative net income.
  • ALVAL had a negative operating cash flow in each of the past 5 years.
ALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFALVAL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M

1.2 Ratios

  • With a Return On Assets value of -55.87%, ALVAL is not doing good in the industry: 67.47% of the companies in the same industry are doing better.
  • ALVAL's Return On Equity of -94.60% is in line compared to the rest of the industry. ALVAL outperforms 46.99% of its industry peers.
Industry RankSector Rank
ROA -55.87%
ROE -94.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALVAL.PA Yearly ROA, ROE, ROICALVAL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • ALVAL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALVAL.PA Yearly Profit, Operating, Gross MarginsALVAL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ALVAL.PA Health Analysis

2.1 Basic Checks

  • ALVAL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALVAL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ALVAL.PA Yearly Shares OutstandingALVAL.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALVAL.PA Yearly Total Debt VS Total AssetsALVAL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • Based on the Altman-Z score of 1.19, we must say that ALVAL is in the distress zone and has some risk of bankruptcy.
  • ALVAL has a better Altman-Z score (1.19) than 61.45% of its industry peers.
  • A Debt/Equity ratio of 0.25 indicates that ALVAL is not too dependend on debt financing.
  • ALVAL has a Debt to Equity ratio (0.25) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.19
ROIC/WACCN/A
WACC7.69%
ALVAL.PA Yearly LT Debt VS Equity VS FCFALVAL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M

2.3 Liquidity

  • ALVAL has a Current Ratio of 3.43. This indicates that ALVAL is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ALVAL (3.43) is better than 72.29% of its industry peers.
  • ALVAL has a Quick Ratio of 2.93. This indicates that ALVAL is financially healthy and has no problem in meeting its short term obligations.
  • ALVAL has a Quick ratio of 2.93. This is in the better half of the industry: ALVAL outperforms 63.86% of its industry peers.
Industry RankSector Rank
Current Ratio 3.43
Quick Ratio 2.93
ALVAL.PA Yearly Current Assets VS Current LiabilitesALVAL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. ALVAL.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 15.60% over the past year.
  • The Revenue has grown by 417.14% in the past year. This is a very strong growth!
  • ALVAL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -21.79% yearly.
EPS 1Y (TTM)15.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.7%
Revenue 1Y (TTM)417.14%
Revenue growth 3Y4.86%
Revenue growth 5Y-21.79%
Sales Q2Q%309.29%

3.2 Future

  • Based on estimates for the next years, ALVAL will show a very strong growth in Earnings Per Share. The EPS will grow by 37.52% on average per year.
  • ALVAL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 313.66% yearly.
EPS Next Y26.09%
EPS Next 2Y37.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year438.94%
Revenue Next 2Y313.66%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALVAL.PA Yearly Revenue VS EstimatesALVAL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
ALVAL.PA Yearly EPS VS EstimatesALVAL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. ALVAL.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALVAL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALVAL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALVAL.PA Price Earnings VS Forward Price EarningsALVAL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALVAL.PA Per share dataALVAL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • ALVAL's earnings are expected to grow with 37.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.52%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALVAL.PA Dividend Analysis

5.1 Amount

  • No dividends for ALVAL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALVAL.PA Fundamentals: All Metrics, Ratios and Statistics

VALBIOTIS SA

EPA:ALVAL (3/12/2026, 7:00:00 PM)

1.008

-0.04 (-3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)N/A
Inst Owners2.31%
Inst Owner ChangeN/A
Ins Owners2.99%
Ins Owner ChangeN/A
Market Cap23.89M
Revenue(TTM)905.00K
Net Income(TTM)-11.12M
Analysts85.45
Price Target2.18 (116.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.54%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.91%
EPS NY rev (3m)-17.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-23.01%
Revenue NY rev (3m)-23.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 50.61
P/FCF N/A
P/OCF N/A
P/B 2.03
P/tB 2.25
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.02
BVpS0.5
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.87%
ROE -94.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -263.54%
Cap/Sales 53.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.43
Quick Ratio 2.93
Altman-Z 1.19
F-Score3
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)43.01%
Cap/Depr(5y)41.52%
Cap/Sales(3y)57.02%
Cap/Sales(5y)69.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.7%
EPS Next Y26.09%
EPS Next 2Y37.52%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)417.14%
Revenue growth 3Y4.86%
Revenue growth 5Y-21.79%
Sales Q2Q%309.29%
Revenue Next Year438.94%
Revenue Next 2Y313.66%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.86%
EBIT Next 3Y36.08%
EBIT Next 5Y27.68%
FCF growth 1Y-30.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.83%
OCF growth 3YN/A
OCF growth 5YN/A

VALBIOTIS SA / ALVAL.PA FAQ

What is the fundamental rating for ALVAL stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA.


Can you provide the valuation status for VALBIOTIS SA?

ChartMill assigns a valuation rating of 1 / 10 to VALBIOTIS SA (ALVAL.PA). This can be considered as Overvalued.


What is the profitability of ALVAL stock?

VALBIOTIS SA (ALVAL.PA) has a profitability rating of 0 / 10.


How financially healthy is VALBIOTIS SA?

The financial health rating of VALBIOTIS SA (ALVAL.PA) is 4 / 10.


Can you provide the expected EPS growth for ALVAL stock?

The Earnings per Share (EPS) of VALBIOTIS SA (ALVAL.PA) is expected to grow by 26.09% in the next year.